Compare ASPN & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPN | TARA |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | 854 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.3M | 268.5M |
| IPO Year | 2011 | 2014 |
| Metric | ASPN | TARA |
|---|---|---|
| Price | $3.26 | $4.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.25 | ★ $21.67 |
| AVG Volume (30 Days) | ★ 1.3M | 845.8K |
| Earning Date | 05-07-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $271,103,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $2.77 |
| 52 Week High | $9.78 | $7.82 |
| Indicator | ASPN | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 37.61 |
| Support Level | $2.92 | $2.96 |
| Resistance Level | $3.80 | $5.39 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 32.67 | 0.49 |
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).